News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer.

This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug development and the launch of a new company targeting neurological disorders.

The top stories:

Study of autism types reveals common underlying mechanism

An analysis of how brains with different forms of autism develop has revealed common underlying mechanisms that may respond to existing medications.

R&D partnership to jointly develop new ALS drugs

PrecisionLife and the Nucleic Acid Therapy Accelerator (NATA) have announced a collaboration to co-develop novel oligonucleotide therapies for sporadic motor neurone disease/ALS.

$63m for allosteric modulators for neurological disorders

Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.

EU approves long-acting injectable for schizophrenia

Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia.